tbuckley/cabot-search huggingface dataset:
Study Helps Explain Racial Disparities in Biological Aging
Authors: Emily Harris
Journal: JAMA (2023)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
SETBP1 is dispensable for normal and malignant hematopoiesis
Authors: Atsushi Tanaka, Koutarou Nishimura, Wataru Saika, Ayana Kon, Yui Koike, Hiromi Tatsumi, June Takeda, Masaki Nomura, Weijia Zang, Manabu Nakayama, Masashi Matsuda, Hiromi Yamazaki, Miki Fukumoto, Hiromi Ito, Yasutaka Hayashi, Toshio Kitamura, Hiroshi Kawamoto, Akifumi Takaori-Kondo, Haruhiko Koseki, Seishi Ogawa, Daichi Inoue
Journal: Leukemia (2023)
Error in Author Surname in Byline
Authors: Chun-Chan Zheng, Xiao-Xuan Chen, Rui-Tao Zou, Gui-Yue Cai, Rong-Yi Chen, X.-X Zheng, R.-Y Chen, X.-X Chen, Cai Zou, Rong-Yi Chen
Journal: JAMA Dermatology (2023)

Margo Waters, BS; Allison Dobry, MD; Stephanie T. Le, MD; Kanade Shinkai, MD, PhD; Thomas M. Beachkofsky, MD; Mark D. P. Davis, MD; Arturo R. Dominguez, MD; Daniela Kroshinsky, MD, MPH; Alina Markova, MD; Robert G. Micheletti, MD; Arash Mostaghimi, MD, MPA, MPH; Helena B. Pasieka, MD, MS; Misha Rosenbach, MD; Lucia Seminario-Vidal, MD, PhD; John Trinidad, MD, MPH; Joerg Albrecht, MD, PhD; Emily M. Altman, MD; Ryan Arakaki, MD; Michael Ardern-Jones, DPhil; Alina G. Bridges, DO; Adela R. Cardones, MD, MHSc; Angad A. Chadha, MD; Jennifer K. Chen, MD; Steven T. Chen, MD, MPH, MHPEd; Kyle Cheng, MD; Steven Daveluy, MD; Katherine L. DeNiro, MD; Joanna Harp, MD; Jesse J. Keller, MD, MCR; Brett King, MD, PhD; Abraham M. Korman, MD; Eve J. Lowenstein, MD, PhD; Erin Luxenberg, MD; Jennifer Brescoll Mancuso, MD; Melissa M. Mauskar, MD; Philip Milam, MD; Kiran Motaparthi, MD; Caroline A. Nelson, MD; Cuong V. Nguyen, MD; Fnu Nutan, MD; Alex G. Ortega-Loayza, MD, MCR; Tejesh Patel, MD; Sahand Rahnama-Moghadam, MD, MS; Sergey Rekhtman, MD, PharmD, MPH; Nathan W. Rojek, MD; Mansi Sarihan, MD; Sheila Shaigany, MD; Timmie R. Sharma, MD; Sabrina M. Shearer, MD; Bridget E. Shields, MD; Lindsay C. Strowd, MD; Danielle M. Tartar, MD, PhD; Cristina Thomas, MD; Karolyn A. Wanat, MD; Andrew C. Walls, MD; Lisa C. Zaba, MD, PhD; Carolyn M. Ziemer, MD, MPH; Emanual Maverakis, MD; Benjamin H. Kaffenberger, MD, MS
Shortened TB Regimen Not Effective
Authors: Emily Harris
Journal: JAMA (2023)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Pharmacological inhibition of METTL3 impacts specific haematopoietic lineages
Authors: Katherine Sturgess, Eliza Yankova, M. S. Vijayabaskar, Tomoya Isobe, Justyna Rak, Iwo Kucinski, Melania Barile, Natalie A. Webster, Maria Eleftheriou, Rebecca Hannah, Malgorzata Gozdecka, George Vassiliou, Oliver Rausch, Nicola K. Wilson, Berthold Göttgens, Konstantinos Tzelepis
Journal: Leukemia (2023)
Concerns About a Frailty Screening Initiative and Postoperative Mortality
Authors: Xiaoqian Zhang, Zhixin Zhang, Wenquan Niu
Journal: JAMA Surgery (2023)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Safety and efficacy of jaktinib (a novel<scp>JAK</scp>inhibitor) in patients with myelofibrosis who are relapsed or refractory to ruxolitinib: A<scp>single‐arm</scp>,<scp>open‐label</scp>, phase 2, multicenter study
Authors: Yi Zhang, Qike Zhang, Qingchi Liu, Huibing Dang, Sujun Gao, Wei Wang, Hu Zhou, Yuqing Chen, Liangming Ma, Jishi Wang, Haiping Yang, Binhua Lu, Hewen Yin, Liqing Wu, Shanshan Suo, Qingwei Zhao, Hongyan Tong, Jie Jin
Journal: American Journal of Hematology (2023)

Ruxolitinib has demonstrated efficacy in patients with myelofibrosis (MF). However, substantial number of patients may not respond after 3-6 months of treatment or develop resistance over time. In this phase 2 trial, patients with a current diagnosis of intermediate or high-risk MF who either had an inadequate splenic response or spleen regrowth after ruxolitinib treatment were enrolled. All patients received jaktinib 100 mg Bid. The primary endpoint was the proportion of patients with ≥35% reduction in spleen volume (SVR 35) at week 24. The secondary endpoints included change of MF-related symptoms, anemic response, and safety profile. From July 6, 2021, to January 24, 2022, 34 ruxolitinib-refractory or relapsed patients were enrolled, 52.9% (18 of 34) were DIPSS intermediate 2 or high risk. SVR 35 at week 24 was 32.4% (11 of 34, 95% CI 19.1%-49.2%) in all patients and 33.3% (6 of 18, 95% CI 16.3%-56.3%) in the intermediate 2 or high-risk group. A total of 50% (8 of 16) transfusion-independent patients with hemoglobin (HGB) <100 g/L at baseline had HGB elevation ≥20 g/L within 24 weeks. Furthermore, 46.4% (13 of 28) of patients had a ≥ 50% decrease in the total symptom score (TSS 50) at week 24. The most common grade ≥3 treatment-emergent adverse events (TEAEs) were thrombocytopenia (32.4%), anemia (32.4%), and leukocytosis (20.6%). In total, 13 (38.2%) of 34 patients had serious adverse events (SAE), of which drug-related SAEs were found in 5 patients (14.7%). These results indicate that jaktinib can be a promising treatment option for patients with MF who have either become refractory to or relapsed after ruxolitinib treatment.
The Effect of Racial Concordance on Patient Trust in Online Videos About Prostate Cancer
Authors: Stacy Loeb, Joseph E. Ravenell, Scarlett Lin Gomez, Hala T. Borno, Katherine Siu, Tatiana Sanchez Nolasco, Nataliya Byrne, Godfrey Wilson, Derek M. Griffith, Rob Crocker, Robert Sherman, Samuel L. Washington, Aisha T. Langford
Journal: JAMA Network Open (2023)

Importance Black men have a higher risk of prostate cancer compared with White men, but Black adults are underrepresented in online content about prostate cancer. Across racial groups, the internet is a popular source of health information; Black adults are more likely to trust online health information, yet have more medical mistrust than White adults. Objective To evaluate the association between racial representation in online content about prostate cancer and trust in the content and identify factors that influence trust. Design, Setting, and Participants A randomized clinical trial was conducted from August 18, 2021, to January 7, 2022, consisting of a 1-time online survey. Participants included US men and women aged 40 years and older. Data were analyzed from January 2022 to June 2023. Interventions Participants were randomized to watch the same video script about either prostate cancer screening or clinical trials presented by 1 of 4 speakers: a Black physician, a Black patient, a White physician, or a White patient, followed by a questionnaire. Main Outcomes and Measures The primary outcome was a published scale for trust in the information. χ 2 tests and multivariable logistic regression were used to compare trust according to the video’s speaker and topic. Results Among 2904 participants, 1801 (62%) were men, and the median (IQR) age was 59 (47-69) years. Among 1703 Black adults, a greater proportion had high trust in videos with Black speakers vs White speakers (72.7% vs 64.3%; adjusted odds ratio [aOR], 1.62; 95% CI, 1.28-2.05; P &amp;amp;lt; .001); less trust with patient vs physician presenter (64.6% vs 72.5%; aOR, 0.63; 95% CI, 0.49-0.80; P &amp;amp;lt; .001) and about clinical trials vs screening (66.3% vs 70.7%; aOR, 0.78; 95% CI, 0.62-0.99; P = .04). Among White adults, a lower proportion had high trust in videos featuring a patient vs physician (72.0% vs 78.6%; aOR, 0.71; 95% CI, 0.54-0.95; P = .02) and clinical trials vs screening (71.4% vs 79.1%; aOR, 0.57; 95% CI, 0.42-0.76; P &amp;amp;lt; .001), but no difference for Black vs White presenters (76.8% vs 73.7%; aOR, 1.11; 95% CI, 0.83-1.48; P = .49). Conclusions and Relevance In this randomized clinical trial, prostate cancer information was considered more trustworthy when delivered by a physician, but racial concordance was significantly associated with trust only among Black adults. These results highlight the importance of physician participation and increasing racial diversity in public dissemination of health information and an ongoing need for public education about clinical trials. Trial Registration ClinicalTrials.gov Identifier: NCT05886751
Treatment of Severe Dermatitis, Multiple Allergies, and Metabolic Wasting With Dupilumab
Authors: Yuta Koike, Takuya Takeichi, Norito Ishii, Tomoka Waseda, Naoya Murayama, Masashi Akiyama, Hiroyuki Murota
Journal: JAMA Dermatology (2023)

This case report describes a woman with severe dermatitis, multiple allergies, and metabolic wasting syndrome.
Intersectional Prevalence of Suicide Ideation, Plan, and Attempt Based on Gender, Sexual Orientation, Race and Ethnicity, and Rurality
Authors: Lauren N. Forrest, Ariel L. Beccia, Cara Exten, Sarah Gehman, Emily B. Ansell
Journal: JAMA Psychiatry (2023)

Suicidal thoughts and behaviors (STBs) are major public health problems, and some social groups experience disproportionate STB burden. Studies assessing STB inequities for single identities (eg, gender or sexual orientation) cannot evaluate intersectional differences and do not reflect that the causes of inequities are due to structural-level (vs individual-level) processes.
Nationwide prospective survey of secondary myelofibrosis in Japan: superiority of DIPSS-plus to MYSEC-PM as a survival risk model
Authors: Kotaro Shide, Katsuto Takenaka, Akira Kitanaka, Akihiko Numata, Takuro Kameda, Takuji Yamauchi, Atsushi Inagaki, Shohei Mizuno, Akiyoshi Takami, Shinichi Ito, Masao Hagihara, Kensuke Usuki, Takaaki Maekawa, Kazutaka Sunami, Yasunori Ueda, Miyuki Tsutsui, Miki Ando, Norio Komatsu, Keiya Ozawa, Mineo Kurokawa, Shunya Arai, Kinuko Mitani, Koichi Akashi, Kazuya Shimoda
Journal: Blood Cancer Journal (2023)
Safety and Efficacy of <scp>Long‐Term</scp> Voclosporin Treatment for Lupus Nephritis in the Phase 3 <scp>AURORA</scp> 2 Clinical Trial
Authors: Amit Saxena, Ellen M. Ginzler, Keisha Gibson, Bancha Satirapoj, Adolfina Elizabeth Zuta Santillán, Olena Levchenko, Sandra Navarra, Tatsuya Atsumi, Shinsuke Yasuda, Nilmo Noel Chavez‐Perez, Cristina Arriens, Samir V. Parikh, Dawn J. Caster, Vanessa Birardi, Simrat Randhawa, Laura Lisk, Robert B. Huizinga, Y. K. Onno Teng
Journal: Arthritis & Rheumatology (2023)

AURORA 2 evaluated the long-term safety, tolerability, and efficacy of voclosporin compared to placebo in patients with lupus nephritis (LN) receiving an additional two years of treatment following completion of the one-year AURORA 1 study.
Forest Disturbance and Disease: Exploring the Effects of Tree Harvesting Area on <i>Cryptococcus gattii</i> sensu lato Infection Risk, Vancouver Island, Canada, 1998–2014
Authors: Emily Sohanna Acheson, Michael Otterstatter, Eleni Galanis
Journal: Environmental Health Perspectives (2023)

Background: The disturbance of colonized trees and soil, such as through forestry activities, has been proposed to disperse soil- and tree-inhabiting fungal pathogens. Cryptococcus gattii sensu lato is one such pathogen that was detected on Vancouver Island, British Columbia, Canada, beginning in 1999 and caused human and animal illness. Objectives: Our aim was to determine if C. gattii s.l. human case incidence on Vancouver Island was correlated with the intensity of landscape-level tree harvesting occurring near human settlement areas. Methods: We created buffers around human settlement areas with radii increments of 2.5km, from 2.5 to 20km, and summed the area of annual tree harvests occurring within each buffer zone. We then performed Spearman rank–order correlation to measure the association between case incidence and annual tree harvest intensity at each radius from 1998 through 2014. Results: The incidence of C. gattii was positively correlated with tree harvesting intensity only at distances of 7.5km (r=0.66, p=0.004) and 10km (r=0.64, p=0.005) from human settlement areas. As annual tree harvesting area increased between 1999 and 2003, so did annual C. gattii incidence in humans, before both plateaued around 2002 and decreased after 2007. Discussion: Our findings suggest that tree harvesting plays a role in the spread of C. gattii on Vancouver Island. This may be due to tree cutting or soil disturbance facilitating the aerosolization of spores to increase infection risk. This research also illustrates the contribution that geographic information systems can make to public health research on environmental disturbance and disease outbreaks. https://doi.org/10.1289/EHP12396
Errors in Affiliation and Funding Statement
Authors: Caroline Park
Journal: JAMA Surgery (2023)

Caroline Park, MD, PhD; Ankur Bharija, MD; Matthew Mesias, MD; Ann Mitchell, RN, MSN, CNS, PHN; Purnima Krishna, MSN, MBA, RN; Nannette Storr-Street, RN, MS, AG-CNS-BC; Alyssa Brown, MS, OTR/L; Marina Martin, MD, MPH; Amy C. Lu, MD, MPH; Kristan L. Staudenmayer, MD
Single-cell RNA-seq reveals alterations in peripheral CX3CR1 and nonclassical monocytes in familial tauopathy
Authors: Daniel W. Sirkis, Caroline Warly Solsberg, Taylor P. Johnson, Luke W. Bonham, Virginia E. Sturm, Suzee E. Lee, Katherine P. Rankin, Howard J. Rosen, Adam L. Boxer, William W. Seeley, Bruce L. Miller, Ethan G. Geier, Jennifer S. Yokoyama
Journal: Genome Medicine (2023)

Abstract Background Emerging evidence from mouse models is beginning to elucidate the brain’s immune response to tau pathology, but little is known about the nature of this response in humans. In addition, it remains unclear to what extent tau pathology and the local inflammatory response within the brain influence the broader immune system. Methods To address these questions, we performed single-cell RNA sequencing (scRNA-seq) of peripheral blood mononuclear cells (PBMCs) from carriers of pathogenic variants in MAPT , the gene encoding tau ( n = 8), and healthy non-carrier controls ( n = 8). Primary findings from our scRNA-seq analyses were confirmed and extended via flow cytometry, droplet digital (dd)PCR, and secondary analyses of publicly available transcriptomics datasets. Results Analysis of ~ 181,000 individual PBMC transcriptomes demonstrated striking differential expression in monocytes and natural killer (NK) cells in MAPT pathogenic variant carriers. In particular, we observed a marked reduction in the expression of CX3CR1 —the gene encoding the fractalkine receptor that is known to modulate tau pathology in mouse models—in monocytes and NK cells. We also observed a significant reduction in the abundance of nonclassical monocytes and dysregulated expression of nonclassical monocyte marker genes, including FCGR3A . Finally, we identified reductions in TMEM176A and TMEM176B , genes thought to be involved in the inflammatory response in human microglia but with unclear function in peripheral monocytes. We confirmed the reduction in nonclassical monocytes by flow cytometry and the differential expression of select biologically relevant genes dysregulated in our scRNA-seq data using ddPCR. Conclusions Our results suggest that human peripheral immune cell expression and abundance are modulated by tau-associated pathophysiologic changes. CX3CR1 and nonclassical monocytes in particular will be a focus of future work exploring the role of these peripheral signals in additional tau-associated neurodegenerative diseases.
LncRNA AGPG Confers Endocrine Resistance in Breast Cancer by Promoting E2F1 Activity
Authors: Shiyi Yu, Ying Wang, Xue Gong, Zhehao Fan, Zheng Wang, Zhengyan Liang, Rui Wu, Binjie Cao, Ning Wang, Caili Bi, Dan Lv, Haibo Sun
Journal: Cancer Research (2023)

Resistance to endocrine therapy represents a major concern for patients with estrogen receptor α-positive (ERα+) breast cancer. Endocrine therapy resistance is commonly mediated by activated E2F signaling. A better understanding of the mechanisms governing E2F1 activity in resistant cells could reveal strategies for overcoming resistance. Here, we identified the long noncoding RNA (lncRNA) actin gamma 1 pseudogene 25 (AGPG) as a regulator of E2F1 activity in endocrine-resistant breast cancer. Expression of AGPG was increased in endocrine-resistant breast cancer cells, which was driven by epigenomic activation of an enhancer. AGPG was also abnormally upregulated in patient breast tumors, especially in the luminal B subtype, and high AGPG expression was associated with poor survival of patients with ERα+ breast cancer receiving endocrine therapy. The upregulation of AGPG mediated resistance to endocrine therapy and cyclin-dependent kinase 4/6 inhibition in breast cancer cells. Mechanistically, AGPG physically interacted with PURα, thus releasing E2F1 from PURα and leading to E2F1 signaling activation in ERα+ breast cancer cells. In patients with breast cancer, E2F1 target genes were positively and negatively correlated with expression of AGPG and PURα, respectively. Coadministration of chemically modified AGPG siRNA and tamoxifen strongly suppressed tumor growth in endocrine-resistant cell line-derived xenografts. Together, these results demonstrate that AGPG can drive endocrine therapy resistance and indicate that it is a promising biomarker and potential therapeutic target in breast cancer.Blockade of formation of the PURα/E2F1 complex by lncRNA AGPG activates E2F1 and promotes endocrine resistance, providing potential strategies for combatting endocrine-resistant breast cancer.
Water and Sanitation Crisis Affects Women and Girls Most
Authors: Emily Harris
Journal: JAMA (2023)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal